US Patent
US8479730 — Inhaler device
Formulation · Assigned to Novartis AG · Expires 2028-10-11 · 2y remaining
Vulnerability score
55/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects an inhaler device for powdered medicaments, specifically designed to hold a capsule and pierce it to release the medicament.
USPTO Abstract
An inhaler device ( 1 ) for powdered medicaments. The device ( 1 ) has a body ( 5 ) that has a recess ( 50 ) for holding a capsule containing a powdered medicament to be inhaled, at least one air passage ( 90 ) that is tangentially disposed to the recess ( 50 ) , and a mouthpiece ( 30 ) that includes a coaxially disposed inhalation passage ( 70 ) that communicates with the recess ( 50 ) of the body ( 5 ). The body ( 5 ) has a pair of opposed spring ( 105 ) biased push-buttons ( 40 ) that each include at least one piercing element ( 95 ) for piercing the capsule when loaded in the recess ( 50 ). The medicament is released from the pierced capsule when air is drawn through the air passage(s) ( 90 ) into the recess ( 50 ) and swirled about therein. The mouthpiece ( 30 ) is pivotally attached to the edge of the body ( 5 ) so that it is pivotable between an open loading position and a closed dispensing position about an axis that is perpendicular to the longitudinal axis of the inhaler ( 1 ).
Drugs covered by this patent
- glycopyrrolate (Glycopyrrolate) · Yonsei University
- indacaterol-maleate (INDACATEROL MALEATE)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.